Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2003

View Archived Issues

Kappa opioid receptor antagonist with antidepressant-like effects

First-quarter highlights at Avant

Introgen gains license to fus1 anticancer gene

Progress made in Bexxar review

Shire summarizes R&D highlights for the first quarter

Dry eye symptoms improve after transdermal application of testosterone cream

Extended-release ciprofloxacin in complicated urinary tract infections

Improved retinal thickness found with midostaurin in diabetic macular edema

Tetracyclic 5-HT receptor modulators identified by Pharmacia (Pfizer)

New smooth muscle-selective muscarinic antagonists covered by Kyorin patent

Alpha7 nicotinic agonists with utility in cognition disorders, psychosis, etc.

Tetrazole-based mGluR5 antagonists in early development at Merck

Gedeon Richter presents three series of selective dopamine D3 receptor modulators

Wyeth scientists prepare and test two series of 5-HT6 receptor ligands

Novel helicoidal urea-containing oligomers with antifungal and antibacterial activity

TACE inhibitors, their preparation and use described in Kaken patent

Novartis advances Medarex antibody into clinical development

Updated phase II results for Tocosol Paclitaxel

Schering AG and Astex enter drug discovery collaboration

Neurogenetics licenses phase II compound from Lilly

New Risperdal formulation launched

Inhibitex presents results from first Veronate clinical study

StreptAvax stimulates broad immune response in phase II study

VNS Therapy effective in children with resistant seizures

Rat study suggests potential of topiramate in treating nicotine addiction

Development of memantine for neuropathic pain under review following pivotal results

Kucera reveals anti-HIV small molecule with novel mechanism of action in Savannah

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...